MediWound (MDWD) Expected to Announce Earnings on Thursday

MediWound (NASDAQ:MDWD) is projected to announce its Q3 2025 results before the market opens on Thursday, November 20th. Analysts expect the company to announce earnings of ($0.81) per share and revenue of $6.5620 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 20, 2025 at 8:30 AM ET.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.68). The company had revenue of $5.71 million for the quarter, compared to analyst estimates of $5.68 million. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%. On average, analysts expect MediWound to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MediWound Stock Performance

MDWD opened at $18.22 on Thursday. The company has a market capitalization of $202.01 million, a P/E ratio of -6.90 and a beta of 0.22. The company has a 50-day moving average of $17.95 and a 200-day moving average of $18.83. MediWound has a 1-year low of $14.14 and a 1-year high of $22.50.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on MDWD shares. Wall Street Zen lowered MediWound from a “hold” rating to a “sell” rating in a report on Friday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research report on Wednesday, October 8th. Finally, Zacks Research lowered MediWound from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Four investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $32.25.

Institutional Investors Weigh In On MediWound

A number of hedge funds have recently added to or reduced their stakes in MDWD. Marshall Wace LLP bought a new position in shares of MediWound during the second quarter worth about $317,000. Jane Street Group LLC acquired a new position in MediWound during the 2nd quarter valued at about $295,000. Envestnet Asset Management Inc. bought a new position in MediWound in the 3rd quarter worth about $243,000. The Manufacturers Life Insurance Company increased its stake in shares of MediWound by 104.4% in the second quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 13,312 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.